Vitrolife Group (VITR) Q2 2026 earnings summary

Executive summary

• Record revenue in Consumables at SEK 358 million, with 15% organic growth in Americas; net income reached SEK 129 million and EPS was SEK 0.95 for Q2 2026.

• Launched EmbryoCath and EmbryoViewer Pro, expanding into the embryo transfer segment and advancing IVF technology innovation.

• Strategic focus on profitable growth, innovation, and operational excellence, with actions to optimize cost base and restructure operations.

• Restructuring and portfolio rationalization, including exits from low-profit product lines, supported profitability.

• Share repurchase program of up to SEK 500 million announced post-period.

Financial highlights

• Net sales were SEK 857 million, representing a 2% decrease in SEK but 1% organic growth in local currencies excluding exited business.

• Gross margin improved to 60.3% (up from 58.0% year-over-year), driven by product mix and operational efficiency.

• EBITDA was SEK 295 million (margin 34.4%, up from 27.8% last year), positively impacted by one-off items.

• Net income increased to SEK 129 million from SEK 100 million year-over-year; EPS rose to SEK 0.95 from SEK 0.74.

• Operating cash flow was SEK 140 million, impacted by increased receivables and inventory build-up.

Outlook and guidance

• Continued focus on profitable growth through market segmentation, innovation, and operational excellence, with further product launches and digital investments planned.

• Market softness expected to persist in China and Middle East due to structural and geopolitical factors.

• IVF cycle demand expected to grow mid-single digit globally in coming years, driven by demographic trends and improved reimbursement.

• Board-approved share repurchase program up to SEK 500 million through AGM 2027, in addition to dividend policy.

• Long-term financial targets: annual organic growth >10%, EBITDA margin >33%, net debt/EBITDA <3.